Lil­ly wins FDA ap­proval for sec­ond in­ter­change­able in­sulin biosim­i­lar

The emer­gence of in­ter­change­able biosim­i­lars since the path­way opened up has been slow. But the FDA on Thurs­day ap­proved the fourth in­ter­change­able biosim­i­lar, which is al­so the sec­ond in­ter­change­able biosim­i­lar in­sulin prod­uct.

Eli Lil­ly’s Rezvoglar (in­sulin glargine-aglr), which con­vert­ed to an in­ter­change­able af­ter an ear­li­er biosim­i­lar ap­proval in De­cem­ber 2021, fol­lows Vi­a­tris’ Sem­glee in seek­ing out a niche to com­pete with Sanofi’s block­buster Lan­tus (in­sulin glargine).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.